Fresh Tracks Therapeutics (FRTX) Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and.
The findings may help explain shared clinical immune features between people with Down syndrome and older individuals. such as increased autoimmunity and impaired vaccine response.
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.